PUBLISHER: Grand View Research | PRODUCT CODE: 1888612
PUBLISHER: Grand View Research | PRODUCT CODE: 1888612
The global targeted DNA RNA sequencing market size was estimated at USD 7.40 billion in 2024 and is projected to reach USD 34.56 billion by 2033, expanding at a CAGR of 18.98% from 2025 to 2033. The market is growing rapidly due to the increasing use of precision medicine, the rising incidence of cancer and genetic diseases, and the demand for more cost-efficient and highly accurate sequencing methodologies that enable the deep analysis of specific genes or genomic regions.
Growing Demand for Precision Diagnostics and Targeted Therapies
With the rising incidences of diseases such as cancer, heart diseases, and genetic disorders, the need to diagnose and develop specific treatments drives the market growth. In targeted sequencing, it is possible to identify pathogenic variations at an earlier stage in the process, which facilitates diagnosis and improves treatment options. This is particularly sensitive if the cancer type can be treated with targeted therapy that may not cause as many side effects as chemotherapy.
Moreover, targeted sequencing facilitates the transition to personalized, less invasive therapies, particularly in the fields of oncology and rare disease. By identifying actionable genetic mutations, clinicians can select targeted therapies that are both more effective and have lower toxicity compared to standard chemotherapy or broad-spectrum treatments. The capacity for individualized care, minimal toxicity, and improved patient outcomes continues to drive the use of targeted sequencing in the clinical, research, and pharmaceutical sectors, making it a major contributor to healthcare innovation and market expansion.
Technological Advancements and Cost Efficiency Accelerating Adoption
Advances in next-generation sequencing platforms, enrichment chemistry, and automation make targeted sequencing faster, more accurate, and significantly less costly. Innovations such as improved capture kits, high-throughput systems, and enhanced reagents are reducing processing and turnaround times, thereby supporting applications in hospitals, research laboratories, and biotech companies.
Moreover, targeted sequencing focuses on only selected gene regions, allowing for deeper coverage and increased sensitivity in detecting rarer variants, which is superior to whole-genome sequencing. Given that targeted sequencing has lower data analysis requirements, fewer storage needs, and cost-efficient workflows, it is increasingly chosen by healthcare providers in areas such as routine diagnostics, precision medicine, and large genomic programs. This value proposition, based on efficiencies, continues to drive market expansion.
Global Targeted DNA RNA Sequencing Market Report Segmentation
This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global targeted DNA RNA sequencing market based on technology, workflow, application, type, end use, and region: